Supportive Care in Cancer

, Volume 20, Issue 8, pp 1601–1611

Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: a nurse’s perspective

  • Krista M. Rubin
  • Karen Vona
  • Kathleen Madden
  • Suzanne McGettigan
  • Ilana M. Braun
Review Article



The aim of this review was to examine the toxicity profile of adjuvant interferon (IFN) alfa-2b in melanoma patients from a nursing perspective and to summarize practical information to guide the effective management of common IFN toxicities to improve patient comfort.


This is a narrative summary of both research and review articles identified by searching PubMed, National Cancer Institute, and American Cancer Society websites. It also assesses recognized guidelines on the management of adjuvant IFN toxicity relevant to nurses who are caring for patients receiving adjuvant IFN therapy.


Adjuvant high-dose IFN alfa-2b (HDI) as compared with observation significantly prolongs relapse-free survival in patients with melanoma at high risk for recurrence after surgical resection; however, treatment compliance and patient quality of life can be compromised by its toxicity profile. HDI toxicities affect a number of organ systems and the majority of patients will experience some side effects. Common toxicities such as flu-like symptoms, fatigue, anorexia, neuropsychiatric symptoms, and laboratory abnormalities are discussed, along with both pharmacological and nonpharmacological management strategies.


The considerable side effects of HDI can be managed using established strategies. Oncology nurses play a significant role in the management of patients with melanoma receiving adjuvant HDI, and their prompt recognition of side effects, together with an understanding of effective pharmacological and nonpharmacological interventions, will improve patient comfort; this has the potential to positively influence treatment adherence and completion of the recommended treatment course.


Adjuvant Adverse effects Interferon alfa Therapy management 


  1. 1.
    American Cancer Society (2012) Cancer facts & figures 2012. American Cancer Society. Accessed 14 Feb 2012
  2. 2.
    Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA (2009) Increasing burden of melanoma in the United States. J Invest Dermatol 129(7):1666–1674. doi:10.1038/jid.2008.423 PubMedCrossRefGoogle Scholar
  3. 3.
    Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (2011) SEER cancer statistics review, 1975–2008. National Cancer Institute, Bethesda. Accessed 14 Feb 2012
  4. 4.
    Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206. doi:10.1200/JCO.2009.23.4799 PubMedCrossRefGoogle Scholar
  5. 5.
    Mocellin S, Pasquali S, Rossi CR, Nitti D (2010) Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 102(7):493–501. doi:10.1093/jnci/djq009 PubMedCrossRefGoogle Scholar
  6. 6.
    Rubin KM, Lawrence DP (2009) Your patient with melanoma: staging, prognosis, and treatment. Oncology (Williston Park) 23(8 Suppl):13–21Google Scholar
  7. 7.
    Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH (2000) High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18(12):2444–2458PubMedGoogle Scholar
  8. 8.
    Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U (2001) High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19(9):2370–2380PubMedGoogle Scholar
  9. 9.
    Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14(1):7–17PubMedGoogle Scholar
  10. 10.
    Hauschild A, Gogas H, Tarhini A, Middleton MR, Testori A, Dréno B, Kirkwood JM (2008) Practical guidelines for the management of interferon-α-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 112(5):982–994. doi:10.1002/cncr.23251 PubMedCrossRefGoogle Scholar
  11. 11.
    Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, Donnelly S, Stover L (2002) Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 20(17):3703–3718PubMedCrossRefGoogle Scholar
  12. 12.
    Merck & Co. Inc. (2011) Product information. Intron® A interferon alfa-2b, recombinant for injection. Accessed 26 Sep 2011
  13. 13.
    Haeuber D (1995) The flu-like syndrome. In: Rieger P (ed) Biotherapy: a comprehensive overview. Jones and Bartlett, Boston, pp 243–258Google Scholar
  14. 14.
    Grant M (1997) Nausea and vomiting, quality of life, and the oncology nurse. Oncol Nurs Forum 24(7):5–7PubMedGoogle Scholar
  15. 15.
    National Comprehensive Cancer Network (2010) NCCN Clinical Practice Guidelines in Oncology™ Antiemesis. Accessed 8 Feb 2012
  16. 16.
    Malik UR, Makower DF, Wadler S (2001) Interferon-mediated fatigue. Cancer 92(6 Suppl):1664–1668. doi:10.1002/1097-0142(20010915)92:6+<1664::AID-CNCR1494>3.0.CO;2-9PubMedCrossRefGoogle Scholar
  17. 17.
    Eckert RM (2001) Understanding anticipatory nausea. Oncol Nurs Forum 28(10):1553–1558PubMedGoogle Scholar
  18. 18.
    Piper BF, Rieger PT, Brophy L, Haeuber D, Hood LE, Lyver A, Sharp E (1989) Recent advances in the management of biotherapy-related side effects: fatigue. Oncol Nurs Forum 16(6 Suppl):27–34PubMedGoogle Scholar
  19. 19.
    Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Sales F, Gore M, Mackie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U (2008) Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 372(9633):117–126. doi:10.1016/S0140-6736(08)61033-8 PubMedCrossRefGoogle Scholar
  20. 20.
    Wells JN, Fedric T (2001) Helping patients manage cancer-related fatigue. Home Healthc Nurse 19(8):486–493PubMedCrossRefGoogle Scholar
  21. 21.
    Johnson JE, Nail LM, Lauver D, King KB, Keys H (1988) Reducing the negative impact of radiation therapy on functional status. Cancer 61(1):46–51PubMedCrossRefGoogle Scholar
  22. 22.
    Clark PM, Lacasse C (1998) Cancer-related fatigue: clinical practice issues. Clin J Oncol Nurs 2(2):45–53PubMedGoogle Scholar
  23. 23.
    Kiley KE, Gale DM (1998) Nursing management of patients with malignant melanoma receiving adjuvant alpha interferon-2b. Clin J Oncol Nurs 2(1):11–16PubMedGoogle Scholar
  24. 24.
    Ream E, Richardson A (1999) From theory to practice: designing interventions to reduce fatigue in patients with cancer. Oncol Nurs Forum 26(8):1295–1303PubMedGoogle Scholar
  25. 25.
    Schwartz AL (1998) Patterns of exercise and fatigue in physically active cancer survivors. Oncol Nurs Forum 25(3):485–491PubMedGoogle Scholar
  26. 26.
    Jean-Pierre P, Figueroa-Moseley CD, Kohli S, Fiscella K, Palesh OG, Morrow GR (2007) Assessment of cancer-related fatigue: implications for clinical diagnosis and treatment. Oncologist 12(Suppl 1):11–21. doi:10.1634/theoncologist.12-S1-11 PubMedCrossRefGoogle Scholar
  27. 27.
    McCorkle R (1987) The measurement of symptom distress. Semin Oncol Nurs 3(4):248–256PubMedCrossRefGoogle Scholar
  28. 28.
    Glaus A (1993) Assessment of fatigue in cancer and non-cancer patients and in healthy individuals. Support Care Cancer 1(6):305–315PubMedCrossRefGoogle Scholar
  29. 29.
    Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL (1999) The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85(5):1186–1196. doi:10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-NPubMedCrossRefGoogle Scholar
  30. 30.
    Smets EM, Garssen B, Bonke B, De Haes JC (1995) The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39(3):315–325PubMedCrossRefGoogle Scholar
  31. 31.
    Piper BF, Dibble SL, Dodd MJ, Weiss MC, Slaughter RE, Paul SM (1998) The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol Nurs Forum 25(4):677–684PubMedGoogle Scholar
  32. 32.
    Hann DM, Jacobsen PB, Azzarello LM, Martin SC, Curran SL, Fields KK, Greenberg H, Lyman G (1998) Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Qual Life Res 7(4):301–310PubMedCrossRefGoogle Scholar
  33. 33.
    Mitchell SA, Beck SL, Hood LE, Moore K, Tanner ER (2007) Putting evidence into practice: evidence-based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs 11(1):99–113. doi:10.1188/07.CJON.99-113 PubMedCrossRefGoogle Scholar
  34. 34.
    National Comprehensive Cancer Network (2012) NCCN Clinical Practice Guidelines in Oncology™ for Cancer-Related Fatigue. Version 1.2012. Accessed 8 Feb 2012
  35. 35.
    Schwartz AL, Thompson JA, Masood N (2002) Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum 29(7):E85–E90PubMedCrossRefGoogle Scholar
  36. 36.
    Friebe A, Horn M, Schmidt F, Janssen G, Schmid-Wendtner MH, Volkenandt M, Hauschild A, Goldsmith CH, Schaefer M (2010) Dose-dependent development of depressive symptoms during adjuvant interferon-{alpha} treatment of patients with malignant melanoma. Psychosomatics 51(6):466–473. doi:10.1176/appi.psy.51.6.466 PubMedGoogle Scholar
  37. 37.
    Capuron L, Fornwalt FB, Knight BT, Harvey PD, Ninan PT, Miller AH (2009) Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals? J Affect Disord 119(1–3):181–185. doi:10.1016/j.jad.2009.02.017 PubMedCrossRefGoogle Scholar
  38. 38.
    American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). American Psychiatric Association, WashingtonCrossRefGoogle Scholar
  39. 39.
    Raison CL, Demetrashvili M, Capuron L, Miller AH (2005) Neuropsychiatric adverse effects of interferon-α: recognition and management. CNS Drugs 19(2):105–123PubMedCrossRefGoogle Scholar
  40. 40.
    Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, Miller AH (2002) Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26(5):643–652. doi:10.1016/S0893-133X(01)00407-9 PubMedCrossRefGoogle Scholar
  41. 41.
    Capuron L, Ravaud A, Miller AH, Dantzer R (2004) Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun 18(3):205–213. doi:10.1016/j.bbi.2003.11.004 PubMedCrossRefGoogle Scholar
  42. 42.
    Fulcher CD, Badger T, Gunter AK, Marrs JA, Reese JM (2008) Putting evidence into practice: interventions for depression. Clin J Oncol Nurs 12(1):131–140. doi:10.1188/08.CJON.131-140 PubMedCrossRefGoogle Scholar
  43. 43.
    Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB, Miller AH (2001) Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344(13):961–966. doi:10.1056/NEJM200103293441303 PubMedCrossRefGoogle Scholar
  44. 44.
    Greenberg DB, Jonasch E, Gadd MA, Ryan BF, Everett JR, Sober AJ, Mihm MA, Tanabe KK, Ott M, Haluska FG (2000) Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer 89(2):356–362PubMedCrossRefGoogle Scholar
  45. 45.
    Hauschild A, Kähler KC, Schäfer M, Fluck M (2008) Interdisciplinary management recommendations for toxicity associated with interferon-alfa therapy. J Dtsch Dermatol Ges 6(10):829–837. doi:10.1111/j.1610-0387.2008.06651.x, 829–838PubMedGoogle Scholar
  46. 46.
    Adams F, Fernandez F, Mavligit G (1988) Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities. J Neurooncol 6(4):355–359PubMedCrossRefGoogle Scholar
  47. 47.
    Jonasch E, Haluska FG (2001) Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6(1):34–55PubMedCrossRefGoogle Scholar
  48. 48.
    Daud AI, Xu C, Hwu WJ, Urbas P, Andrews S, Papadopoulos NE, Floren LC, Yver A, Deconti RC, Sondak VK (2011) Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon alpha-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol 67(3):657–666. doi:10.1007/s00280-010-1326-9 PubMedCrossRefGoogle Scholar
  49. 49.
    Wong SF, Jakowatz JG, Taheri R (2004) Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma. Ann Pharmacother 38(10):1655–1659. doi:10.1345/aph.1D546aph.1D546 PubMedCrossRefGoogle Scholar
  50. 50.
    Hughes M (1996) Sexuality issues: keeping your cool. Oncol Nurs Forum 23:1597–1600Google Scholar
  51. 51.
    Shell JA (2002) Evidence-based practice for symptom management in adults with cancer: sexual dysfunction. Oncol Nurs Forum 29(1):53–66PubMedCrossRefGoogle Scholar
  52. 52.
    Britton GR (1999) Selective serotonin reuptake inhibitors: implications for advanced nursing practice. J Am Acad Nurse Pract 11(9):389–395PubMedCrossRefGoogle Scholar
  53. 53.
    Lovejoy NC, Tabor D, Deloney P (2000) Cancer-related depression: part II—neurologic alterations and evolving approaches to psychopharmacology. Oncol Nurs Forum 27(5):795–808PubMedGoogle Scholar
  54. 54.
    Ferrell BR, Dow KH, Leigh S, Ly J, Gulasekaram P (1995) Quality of life in long-term cancer survivors. Oncol Nurs Forum 22(6):915–922PubMedGoogle Scholar
  55. 55.
    Rieger P (ed) (1995) Biotherapy: a comprehensive overview. Jones and Bartlett, SudburyGoogle Scholar
  56. 56.
    Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354(7):709–718. doi:10.1056/NEJMoa053007 PubMedCrossRefGoogle Scholar
  57. 57.
    Gisslinger H, Gilly B, Woloszczuk W, Mayr WR, Havelec L, Linkesch W, Weissel M (1992) Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. Clin Exp Immunol 90(3):363–367PubMedCrossRefGoogle Scholar
  58. 58.
    Jones TH, Wadler S, Hupart KH (1998) Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha. Semin Oncol 25(1 Suppl 1):54–63PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Krista M. Rubin
    • 1
  • Karen Vona
    • 2
  • Kathleen Madden
    • 3
  • Suzanne McGettigan
    • 4
  • Ilana M. Braun
    • 5
  1. 1.Center for MelanomaMassachusetts General Hospital Cancer CenterBostonUSA
  2. 2.Department of MedicineRoswell Park Cancer InstituteBuffaloUSA
  3. 3.Clinical Cancer CenterNew York University Langone Medical CenterNew YorkUSA
  4. 4.Abramson Cancer CenterUniversity of Pennsylvania Health SystemPhiladelphiaUSA
  5. 5.Department of Psychosocial Oncology and Palliative CareDana-Farber Cancer InstituteBostonUSA

Personalised recommendations